BioAtla Investor Presentation Deck

Phase 2 part 1 BA3011 NSCLC initial interim analysis confirms Phase 1 signal supports advancing preparations for part 2 in refractory NSCLC Enrolled Dosed/ 0 scan Not yet dosed W/D consent Efficacy evaluable bicatla # Patients 24 6 (3 combo) 2 2 14 Interim data Data cut-off of Oct 28, 2022 ORR (%) 60 50 40 30 20 10 0 36% 5/14 NSQ+SQ 42% 5/12 All NSQ 50% 4*/8 NSQ monotherapy 57% 4*/7 NSQ mono PD-1 Failure W/D withdrew; NSQ - non-squamous; SQ - squamous Responses include 4 partial responses (*) and one complete response (**) 25% 1**/4 NSQ BA3011 + nivolumab 0/2 SQ BioAtla| Overview 18

View entire presentation